CYTOPROTECTIVE EFFECT OF ALPHA-1 ACID GLYCOPROTEIN ON THE EXPERIMENTAL MODEL OF RENAL REPERFUSION INJURY
https://doi.org/10.24884/1561-6274-2018-22-1-91-97
Abstract
Orozin (alpha-1 acid glycoprotein) pharmacological activity was studied on the experimental model of Kidney Ischemia-Reperfusion (K I/R). Actovegin was used as reference product.
The aim: to evaluate Orozin effects in kidney ischemia-reperfusion (K I/R) experimental model.
Matherial and methods: Male Wistar rats were carried out right-handed nephrectomy followed by mechanical clamping of the vascular bundle of the left kidney during 45 minutes and subsequent reperfusion. Drugs administrated intravemous in two steps: 10 minutes before stop mechanical clamping of the left kidney vascular bundle and 30 minutes after reperfusion. Blood chemistry value (creatinine and urea levels) were used as effectiveness criteria. After 2 and 24 hours of reperfusion the tissues of kidney were collected for histological assays.
Results: Study of experimental model of acute renal faiure showed cytoprotective effect of Orozin confirmed by biochemical and histological analysis.
About the Authors
V. G. Vanatiev
Closed Joint-Stock Company «Saint Petersburg Institute of Pharmacy»
Russian Federation
Russian Federation
Gadzhimagomed V. Vanatiev - Department of general toxicology, toxicologist.
188663, Leningrad region., Vsevolozhsk district, pos. Kuzmolovsky 245, +7(812)6032433
P. V. Burenkov
Closed Joint-Stock Company «Saint Petersburg Institute of Pharmacy»
Russian Federation
Russian Federation
Pavel V. Burenkov - Department of Experimental Pharmacology №1, pharmacologist.
188663, Leningrad region., Vsevolozhsk district, pos. Kuzmolovsky 245, +7(812)6032433
A. G. Lutov
Limited Liability Company «Immuno-Gem»
Russian Federation
Russian Federation
Andrey G. Lutov - Sc.D., Professor.
125212, Moscow, Golovinskoe Highway, build 8/2, +7(495)2326174
M. A. Kovaleva
Closed Joint-Stock Company «Saint Petersburg Institute of Pharmacy»
Russian Federation
Russian Federation
Kovaleva Marya Aleksandrovna - M.D., Head of group pharmacodynamics.
188663, Leningrad region., Vsevolozhsk district, pos. Kuzmolovsky 245, +7 (812) 6032433
М. N. Makarova
Closed Joint-Stock Company «Saint Petersburg Institute of Pharmacy»
Russian Federation
Russian Federation
Marina N. Makarova - M.D., Deputy of general manager for Science.
188663, Leningrad region., Vsevolozhsk district, pos. Kuzmolovsky 245, +7(812) 603-24-33
V. G. Makarov
Closed Joint-Stock Company «Saint Petersburg Institute of Pharmacy»
Russian Federation
Russian Federation
Valeriy G. Makarov - M.D., Professor, general manager.
188663, Leningrad region., Vsevolozhsk district, pos. Kuzmolovsky 245, +7(812)6032433
References
1. Bellomo R et al. Acute renal failure–definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical care 2004; Т. 8 (4); 204. doi: 10.1186/cc2872
2. Johnson RF, Gustin J. Acute renal failure requiring renal replacement therapy in the intensive care unit: impact on prognostic assessment for shared decision making. J Palliat Med 2011 Jul;14(7):883-889. doi: 10.1089/jpm.2010.0452
3. Ympa Y P et al. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J med 2005; 118 (8); 827-832. doi: 10.1016/j.amjmed.2005.01.069
4. Dennen P, Douglas I S, Anderson R. Acute kidney injury in the intensive care unit: an update and primer for the intensivist. Critical care medicine 2010; 38(1); 261-275. doi: 10.1097/CCM.0b013e3181bfb0b5
5. Смирнов АВ, Добронравов ВА, Румянцев АШ и др. Национальные рекомендации. острое повреждение почек: основные принципы диагностики, профилактики и терапии. Часть I. Нефрология 2016; 20(1):79-104 [Smirnov AV, Dobronravov VA, Rumyantsev ASh et al. National guidelines acute kidney injury: basic principles of diagnosis, prevention and therapy. Part I. Nephrology (Saint-Petersburg). 2016; 20(1): 79-104 (In Russ.)]
6. Чукаева ИИ. и др. Уровни показателей острофазового ответа и окислительного стресса у больных острым инфарктом миокарда и их значение в течении заболевания. Вестник РГМУ 2007; (7): 18 [Chukaeva II i dr. Urovni pokazatelei` ostrofazovogo otveta i okislitel`nogo stressa u bol`ny`kh ostry`m infarktom miokarda i ikh znachenie v techenii zabolevaniia. VESTNIK RGMU 2007; (7): 18]
7. Вельков ВВ. С-реактивный белок-в лабораторной диагностике острых воспалений и в оценке рисков сосудистых патологий. Клинико-лабораторный консилиум 2008; 2(21): 37-48 [Vel`kov VV. S-reaktivny`i` belok-v laboratornoi` diagnostike ostry`kh vospalenii` i v ocenke riskov sosudisty`kh patologii`. Cliniko-laboratorny`i` konsilium. 2008; 2(21): 37-48]
8. Попков А. В. и др. Результаты стереометрического анализа состояния передней большеберцовой мышцы при дистракционном, последовательном дистракционнокомпрессионном остеосинтезе голени, в том числе с применением «Орозина» (экспериментально-морфологическое исследование). Гений ортопедии 2002; (2) [Popkov A. V. i dr. Rezul`taty` stereometricheskogo analiza sostoianiia perednei` bol`shebertcovoi` my`shtcy` pri distraktcionnom, posledovatel`nom distraktcionno-kompressionnom osteosinteze goleni, v tom chisle s primeneniem «Orozina» (e`ksperimental`no-morfologicheskoe issledovanie). Genii` ortopedii. 2002; (2)]
9. Huang Z, Ung T. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. Curr Drug Metab 2013;14(2):226-238
10. Нордвик Б. Механизм действия и клиническое применение препарата актовегин. Актовегин. Новые аспекты клинического применения. M., 2002; 18-24 [Nordvik B. Mehanizm dei`stviia i clinicheskoe primenenie preparata aktovegin // Aktovegin. Novy`e aspekty` clinicheskogo primeneniia. M. 2002; 18-24]
11. Макаров ЕВ, Кривохижина ЛВ. Альфа-1-кислый гликопротеин, реактант острой фазы воспаления, как важный гомеостатический фактор организма: обзор литературы. Вестн Южно-Уральск гос университета. Серия: Образование, здравоохранение, физическая культура. 2005; 4(44) [Makarov EV, Krivohizhina LV. Al`fa-1-kisly`i` glikoprotein, reaktant ostroi` fazy` vospaleniia, kak vazhny`i` gomeostaticheskii` faktor organizma: obzor literatury`. Vestneyk Iuzhno-Ural`skogo gosudarstvennogo universiteta. Seriia: Obrazovanie, zdravookhranenie, fizicheskaia kul`tura. 2005; 4(44)]
12. Rabb H et al. Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury. Biochemical and biophysical research communications 1995; 211(1):67-73. doi: 10.1006/bbrc.1995.1779
13. Chertow GM et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. Journal of the American Society of Nephrology 2005; 16(11):3365-3370. doi: 10.1681/ASN.2004090740
14. Голубев АМ и др. Апоптоз при критических состояниях. Общая реаниматология 2006;2(5-6):184-190 [Golubev AM i dr. Apoptoz pri kriticheskikh sostoianiiakh. Obshchaia reanimatologiia. 2006;2(5-6):184-190]
Review
For citations:
Vanatiev V.G., Burenkov P.V., Lutov A.G., Kovaleva M.A., Makarova М.N., Makarov V.G. CYTOPROTECTIVE EFFECT OF ALPHA-1 ACID GLYCOPROTEIN ON THE EXPERIMENTAL MODEL OF RENAL REPERFUSION INJURY. Nephrology (Saint-Petersburg). 2018;22(1):91-97. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-1-91-97
Views:
983
Email this article 